|
|
Vaccine Detail
|
Melanoma DNA vaccine VR1012/mPmel17 |
| Vaccine Information |
- Vaccine Name: Melanoma DNA vaccine VR1012/mPmel17
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0004439
- Type: DNA vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mouse
- Pmel17
gene engineering:
- Type: DNA vaccine construction
- Description:
- Detailed Gene Information: Click Here.
- DNA vaccine plasmid:
- DNA vaccine plasmid name:
- DNA vaccine plasmid VO ID: VO_0000334
- Immunization Route: Intradermal injection (i.d.)
|
| Host Response |
|
Mouse Response
- Vaccine Immune Response Type: VO_0000286
- Efficacy: More than half of the animals that had received VR1012/mPmel17 pDNA were protected completely (eight of 15 = 53.3%) against the highly tumorigenic dose of 1X10^5 M3-7 cells. None of these protected animals developed a tumor at a later time point during an entire observation period of 4 months. By contrast, control animals that had been injected with vector VR1012 pDNA alone consistently failed to reject Pmel17high M3-7 melanoma cells (Wagner et al., 2000).
|
| References |
Wagner et al., 2000: Wagner SN, Wagner C, Lührs P, Weimann TK, Kutil R, Goos M, Stingl G, Schneeberger A. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. The Journal of investigative dermatology. 2000; 115(6); 1082-1087. [PubMed: 11121145].
|
|
